Importantly, the MLL-BRD4 complex binds to histone acetylation marks to recruit POL II in order to control transcriptional elongation [23], and a small molecule inhibitor of BRD4 (i-BET) has shown promise for use in MLL leukemia therapy. Here, KMT2A is linked to leukemia.